Updated April 28th 2025, 16:17 IST
By Dr. Narendra Agrawal
Multiple myeloma is a type of blood cancer that arises from abnormal or malignant plasma cells. Normally, a healthy plasma cell is found in bone marrow and is responsible for producing antibodies to provide immunity to the person. Multiple myeloma can arise when plasma cells transform into malignant plasma cells which leads to the uncontrolled growth of these abnormal plasma cells, which crowd out healthy blood cells. This can cause bone damage, kidney dysfunction, anaemia, and weakened immunity.
The disease is considered incurable but treatable, with therapies aimed at controlling its progression and improving quality of life. According to GLOBOCAN 2022 data, multiple myeloma (MM) accounted for approximately 0.94% of all new cancer cases globally, with an estimated 187,952 new diagnoses and 121,388 deaths in 2022. The age-standardized incidence rate (ASIR) was 0.22%, and the age-standardized mortality rate (ASMR) was 0.13%.
In India, multiple myeloma is increasingly being diagnosed at a younger age, often a decade earlier than in Western countries. A major challenge in younger patients is the low index of suspicion, as physicians may not immediately consider myeloma when individuals present with non-specific symptoms like back pain, fatigue, or fractures. Common symptoms such as spinal fractures, anaemia, paraplegia, and infections further complicate early detection due to their overlap with other conditions. Many patients first seek care from general physicians, leading to prolonged diagnostic delays before reaching specialized oncology centres.
Multiple myeloma treatment has significantly advanced with the introduction of targeted therapies, stem cell transplantation, immunotherapy, and CAR T-cell therapy, offering better disease control and prolonged survival. Targeted therapies, including novel agent drugs, work by specifically attacking cancerous plasma cells while minimizing damage to normal cells.
These drugs serve as the first line of treatment, helping to control the disease and reduce symptoms. For deeper remission, autologous stem cell transplantation is often performed, where a patient’s own stem cells are used to restore healthy bone marrow after high-dose chemotherapy.
For patients who relapse or do not respond to initial treatments, immunotherapy has emerged as a promising option. Monoclonal antibodies and other immune-based treatments help the body’s defense system recognize and attack myeloma cells more effectively. In more resistant cases, CAR T-cell therapy represents a major breakthrough.
This advanced treatment involves extracting the patient’s T-cells, genetically modifying them in a laboratory to target myeloma cells, and then reinfusing them back into the body to enhance their cancer-fighting ability.
Genetic profiling plays a crucial role in treatment selection, as certain high-risk mutations require more aggressive therapeutic strategies. However, despite these innovations, a complete cure remains rare, and patients often require long-term or maintenance therapy.
Early diagnosis is crucial to prevent complications and ensure timely intervention. With ongoing innovations in targeted therapies, immunotherapy, and CAR T-cell therapy, the focus remains on improving quality of life and extending survival.
India has more younger age patients as compared to western world. Younger multiple myeloma patients face unique treatment challenges. Normally a young patient affected from myeloma looks at a productive and long life. So such patients require treatment strategies that can provide them a prolonged disease free duration and a good quality of life.
Many younger age patients present with aggressive disease, including high-risk genetic mutations, necessitating use of immunotherapies and intensive therapies including stem cell transplantation from the outset. The concept is to use most effective drugs in the initial phases of treatment so that to achieve deeper responses which can lead to prolonged disease free life.
For patients who still relapses (recurrence of myeloma), now a days , we have newer treatment modalities like Bispecific antibodies and CAR T-cell therapy, which can salvage many of such patients.
Despite many advancements in treatment, a complete cure remains uncommon, and most patients experience relapses, requiring continuous therapies to manage the disease over the span of years.
(Dr. Narendra Agrawal is the Unit Head and Sr. Consultant, Hemato-Oncology, Leukemia and BMT at Rajiv Gandhi Cancer Institute And Research Centre (RGCIRC).)
Published April 28th 2025, 16:17 IST